Loading...

GYRE GYRE THERAPEUTICS INC US FDA Inspections 8-K Filing

GYR

GYR

GYRE THERAPEUTICS INC

(GYRE)

2026 8-K

Conference Presentation

New Drug Approval

Financial Results Release

Merger Announcement

Drug Application Submitted

Investor Conference Insights

Financial Results

Subsidiary Update

Financial Results Update

Corporate Update

Board Appointment

Equity Offerings

Product Expansion

Investor Meetings

Financial Results

Financial Results

Management Changes

Stock Sale Agreement

Financial Results

Financial Results

Appointment of Director

Annual Meeting and Amendmen...

Approval of Investigational...

Financial Results Announcement

Acquisition of Nintedanib r...

Financial Results Announcement

Appointment of Director

Dismissal of Litigation and...

Amendment to Form 8-K

Business Combination and Na...

Appointment of CEO

Financial Update

Financial Statements and Ex...

Regulation FD Disclosure

Financial Update

Business Combination and Ch...

Business Combination and Na...

Clinical Trial Completion

Business Combination Approval

Agreement Amendment, Certif...

Results of Operations and F...

Dividend Declaration

Delisting Notice

Notice of Delisting

Amendment to Agreements

Termination of Chief Scient...

External Links:

Gyre Therapeutics, Inc. announced on May 12, 2026, that its subsidiary received acceptance of its New Drug Application for F351 (Hydronidone) to treat chronic hepatitis B-induced liver fibrosis. This is a significant event for the company, reflecting positive sentiment as they advance their product in the market.

AI Assistant

GYRE THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.